Fox Run Management L.L.C. Has $527,000 Stake in Kiniksa Pharmaceuticals International, plc $KNSA

Fox Run Management L.L.C. reduced its stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 62.1% in the third quarter, HoldingsChannel.com reports. The firm owned 13,563 shares of the company’s stock after selling 22,180 shares during the period. Fox Run Management L.L.C.’s holdings in Kiniksa Pharmaceuticals International were worth $527,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of KNSA. Arrowstreet Capital Limited Partnership purchased a new position in shares of Kiniksa Pharmaceuticals International during the second quarter valued at approximately $20,349,000. Qube Research & Technologies Ltd raised its position in Kiniksa Pharmaceuticals International by 277.8% in the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after buying an additional 653,236 shares during the last quarter. Rubric Capital Management LP lifted its stake in Kiniksa Pharmaceuticals International by 15.6% during the 2nd quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock valued at $108,184,000 after acquiring an additional 526,567 shares in the last quarter. Cubist Systematic Strategies LLC boosted its holdings in Kiniksa Pharmaceuticals International by 213.2% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock worth $18,192,000 after acquiring an additional 447,536 shares during the last quarter. Finally, Squarepoint Ops LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 186.2% in the 2nd quarter. Squarepoint Ops LLC now owns 416,572 shares of the company’s stock worth $11,527,000 after acquiring an additional 271,005 shares in the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO Mark Ragosa sold 17,845 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $43.28, for a total transaction of $772,331.60. Following the transaction, the chief financial officer owned 12,086 shares of the company’s stock, valued at $523,082.08. This represents a 59.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Eben Tessari sold 12,048 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $41.56, for a total value of $500,714.88. Following the completion of the sale, the chief operating officer directly owned 16,666 shares of the company’s stock, valued at approximately $692,638.96. This trade represents a 41.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 123,623 shares of company stock valued at $5,236,389 over the last ninety days. 53.48% of the stock is currently owned by insiders.

Kiniksa Pharmaceuticals International Stock Performance

Shares of KNSA stock opened at $44.49 on Friday. The firm has a market cap of $3.37 billion, a price-to-earnings ratio of 60.12 and a beta of 0.06. Kiniksa Pharmaceuticals International, plc has a 52 week low of $18.25 and a 52 week high of $49.12. The firm’s 50-day simple moving average is $42.96 and its two-hundred day simple moving average is $39.82.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, February 24th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.12). The company had revenue of $202.13 million for the quarter, compared to analysts’ expectations of $200.86 million. Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.The company’s revenue for the quarter was up 65.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.12) EPS. Analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on KNSA shares. Wedbush increased their target price on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “outperform” rating in a report on Wednesday. Zacks Research upgraded shares of Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research note on Wednesday. Canaccord Genuity Group initiated coverage on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, February 19th. They set a “buy” rating and a $62.00 target price on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, January 22nd. Finally, Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International currently has an average rating of “Moderate Buy” and an average price target of $55.29.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.